PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
About this item
Full title
Author / Creator
Qazilbash, M H , Wieder, E , Thall, P F , Wang, X , Rios, R , Lu, S , Kanodia, S , Ruisaard, K E , Giralt, S A , Estey, E H , Cortes, J , Komanduri, K V , Clise-Dwyer, K , Alatrash, G , Ma, Q , Champlin, R E and Molldrem, J J
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
PR1, an HLA-A2-restricted peptide derived from both proteinase 3 and neutrophil elastase, is recognized on myeloid leukemia cells by cytotoxic T lymphocytes (CTLs) that preferentially kill leukemia and contribute to cytogenetic remission. To evaluate safety, immunogenicity and clinical activity of PR1 vaccination, a phase I/II trial was conducted....
Alternative Titles
Full title
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5332281
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5332281
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2016.254
